Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract C024: Trial in progress: Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors

Shivaani Kummar, Minal Barve, Eric Feldman, Seunghyun Ma, Jaime Merchan, Seock-Ah Im, Sun Young Rha

Mol Cancer Ther (2023) 22 (12_Supplement): C024.

https://doi.org/10.1158/1535-7163.TARG-23-C024

Published: 01 December 2023

View article titled, Abstract C024: Trial in progress: Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors

Journal Articles

Abstract B070: Antitumor effect of AZD5305, a selective PARP1 inhibitor, in breast and gastric cancer cells

Sujin Ham, So Hyeon Kim, Hae Min Hwang, Minyoung Lee, Youlim Noh, Changyun Lee, Yu-Jin Kim, Jinyong Kim, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im

Mol Cancer Ther (2023) 22 (12_Supplement): B070.

https://doi.org/10.1158/1535-7163.TARG-23-B070

Published: 01 December 2023

View article titled, Abstract B070: Antitumor effect of AZD5305, a selective PARP1 inhibitor, in breast and gastric cancer cells

Journal Articles

Abstract C120: Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines

Hae Min Hwang, So Hyeon Kim, Sujin Ham, Minyoung Lee, Youlim Noh, Yu-Jin Kim, Changyun Lee, Jinyoung Kim, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im

Mol Cancer Ther (2023) 22 (12_Supplement): C120.

https://doi.org/10.1158/1535-7163.TARG-23-C120

Published: 01 December 2023

View article titled, Abstract C120: Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines

Journal Articles

Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response

Ahrum Min, Hyemin Jang, Seongyeong Kim, Kyung-Hun Lee, Debora Keunyoung Kim, Koung Jin Suh, Yaewon Yang, Paul Elvin, Mark J. O'Connor, Seock-Ah Im

Mol Cancer Ther (2018) 17 (12): 2507–2518.

https://doi.org/10.1158/1535-7163.MCT-18-0234

Published: 03 December 2018

View article titled, Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response

Includes: Supplementary data

Journal Articles

Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)

Wassim Abida, Yung J. Bang, Louise Carter, Analía Azaro, Matthew Krebs, Seock-Ah Im, Yingxue Chen, Núria Buil-Bruna, Yan Li, David Eaton, Christine Stephens, Graham Ross, Martin Pass, Jordi Rodon, Emma Dean

Mol Cancer Ther (2018) 17 (1_Supplement): A094.

https://doi.org/10.1158/1535-7163.TARG-17-A094

Published: 01 January 2018

View article titled, Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)

Journal Articles

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

Ahrum Min, Seock-Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee-Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae-Yong Kim, Do-Youn Oh, Jeff Brown, Alan Lau, Mark J. O'Connor, Yung-Jue Bang

Mol Cancer Ther (2017) 16 (4): 566–577.

https://doi.org/10.1158/1535-7163.MCT-16-0378

Published: 02 April 2017

View article titled, AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

Includes: Supplementary data

Journal Articles

Src as a Therapeutic Target in Biliary Tract Cancer

Ah-Rong Nam, Ji-Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang

Mol Cancer Ther (2016) 15 (7): 1515–1524.

https://doi.org/10.1158/1535-7163.MCT-16-0013

Published: 05 July 2016

View article titled, Src as a Therapeutic Target in Biliary Tract Cancer

Includes: Supplementary data

Journal Articles

Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.

Do-Youn Oh, Ah-Rong Nam, Tae Yong Kim, Sae-Won Han, Sang-Hyun Song, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang

Mol Cancer Ther (2013) 12 (11_Supplement): C266.

https://doi.org/10.1158/1535-7163.TARG-13-C266

Published: 01 November 2013

View article titled, Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.

Journal Articles

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang

Mol Cancer Ther (2013) 12 (6): 865–877.

https://doi.org/10.1158/1535-7163.MCT-12-0950

Published: 09 June 2013

View article titled, RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Includes: Supplementary data

Journal Articles

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Hyun-Jin Nam, Seock-Ah Im, Do-Youn Oh, Paul Elvin, Hwang-Phill Kim, Young-Kwang Yoon, Ahrum Min, Sang-Hyun Song, Sae-Won Han, Tae-You Kim, Yung-Jue Bang

Mol Cancer Ther (2013) 12 (1): 16–26.

https://doi.org/10.1158/1535-7163.MCT-12-0109

Published: 13 January 2013

View article titled, Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Includes: Supplementary data

Journal Articles

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Hyun-Jin Nam, Keith A. Ching, Julie Kan, Hwang-Phill Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, James G. Christensen, Do-Youn Oh, Yung-Jue Bang

Mol Cancer Ther (2012) 11 (2): 439–451.

https://doi.org/10.1158/1535-7163.MCT-11-0494

Published: 08 February 2012

View article titled, Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Includes: Supplementary data

Journal Articles

Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Seock‐Ah Im, Do Youn Oh, Yung‐Jue Bang, Tae‐You Kim

Mol Cancer Ther (2009) 8 (12_Supplement): A252.

https://doi.org/10.1158/1535-7163.TARG-09-A252

Published: 10 December 2009

View article titled, Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Journal Articles

Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Hyun‐Jin Nam, Hwang‐Phill Kim, Young‐Kwang Yoon, Hyung‐Seok Hur, Maeng‐Sup Kim, Gwan‐Sun Lee, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

Mol Cancer Ther (2009) 8 (12_Supplement): B260.

https://doi.org/10.1158/1535-7163.TARG-09-B260

Published: 10 December 2009

View article titled, Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Journal Articles

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Hyung-Seok Hur, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim

Mol Cancer Ther (2009) 8 (9): 2526–2536.

https://doi.org/10.1158/1535-7163.MCT-09-0300

Published: 17 September 2009

View article titled, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Includes: Supplementary data

Journal Articles

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Hwang-Phill Kim, Sae-Won Han, Sung-Hak Kim, Seock-Ah Im, Do-Youn Oh, Yung-Jue Bang, Tae-You Kim

Mol Cancer Ther (2008) 7 (3): 607–615.

https://doi.org/10.1158/1535-7163.MCT-07-2068

Published: 17 March 2008

View article titled, Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Journal Articles

Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the Rsk and Bad pathways and induces apoptosis in human gastric cancer cells

Keun-Wook Lee, Sang Gyun Kim, Hwang-Phill Kim, Euna Kwon, Jiran You, Hyung-Jun Choi, Jung-Hyun Park, Byeong-Cheol Kang, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang

Mol Cancer Ther (2007) 6 (11_Supplement): B241.

Published: 01 November 2007

View article titled, Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the Rsk and Bad pathways and induces apoptosis in human gastric cancer cells

NARROW

Abstract C024: Trial in progress: Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors

Abstract B070: Antitumor effect of AZD5305, a selective PARP1 inhibitor, in breast and gastric cancer cells

Abstract C120: Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines

Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response

Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

Src as a Therapeutic Target in Biliary Tract Cancer

Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the Rsk and Bad pathways and induces apoptosis in human gastric cancer cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only